Study: Anti-inflammatory drug celecoxib benefits PIK3CA-mutated colon cancer patients

FHS
June 19, 2024
3:12 am

An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation.

Opinion | Medicine, Nazism, and the Holocaust: Essential Lessons for Health Professionals

Czech is a medical historian. Hildebrandt is an anatomy educator. Reis is a family physician. The crimes committed by the Nazi regime, often with the

January 27, 2024

First gene therapy trial aims to restore hearing in children

The aim of this clinical trial, which has just received approval in France, is to assess the safety and efficacy of a new gene therapy

February 5, 2024

Insurers went all-in on Medicare Advantage. Now, some are scaling back

For years, health insurers battled to gain market share in the lucrative privatized Medicare program. Now, the opposite is true. Some of the companies say

September 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.